Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation
Claudia Voena(University of Turin), Paolo Corradini(Gruppo di Ricerca Geriatrica), Alessandra Santoro(Ospedale Vincenzo Cervello), Mauro Malnati(Vita-Salute San Raffaele University), Ignazio Majolino, Vittorio Montefusco(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mario Boccadoro(University of Turin), Giovanni Fagà(Vita-Salute San Raffaele University), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 13
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920